| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
18,220,000 |
| Market
Cap: |
61.77(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9225 - $3.4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Miromatrix Medical is a life sciences company focused on a technology for bioengineering transplantable organs to help save and improve patients' lives. Co.'s Bioengineered Organ Pipeline includes: MiroliverELAP, which is Co.'s External Liver Assist Product and is designed to provide liver dialysis for acute liver failure patients; Miroliver, which is Co.'s implantable bioengineered liver that intended to treat patients with acute and chronic liver failure in collaboration with the Mayo Clinic; and Mirokidney, which is Co.'s implantable bioengineered kidney that intended to treat patients with end-stage renal disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
225,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$360,000 |
| Total People Bought |
0 |
0 |
0 |
8 |
| Total Buy Transactions |
0 |
0 |
0 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Burke Willaim P |
|
– • – |
2023-12-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(67,413) |
0 |
|
- |
|
| Heine Lisa Wipperman |
|
– • – |
2023-12-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(67,413) |
0 |
|
- |
|
| Buckman Paul |
|
– • – |
2023-12-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(54,201) |
0 |
|
- |
|
| Erb John L |
|
– • – |
2023-12-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(54,201) |
0 |
|
- |
|
| Douglas James Michael |
CHIEF FINANCIAL OFFICER |
• – – |
2023-12-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(20,000) |
0 |
|
- |
|
| Maag Peter |
|
– • – |
2023-12-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,368) |
0 |
|
- |
|
| Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-12-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(87,500) |
0 |
|
- |
|
| United Therapeutics Corp |
10% Owner |
– – • |
2023-12-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,419,228 |
|
- |
|
| Burke Willaim P |
|
– • – |
2023-12-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(66,943) |
67,413 |
|
- |
|
| Heine Lisa Wipperman |
|
– • – |
2023-12-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(66,943) |
67,413 |
|
- |
|
| Buckman Paul |
|
– • – |
2023-12-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(52,593) |
54,201 |
|
- |
|
| Erb John L |
|
– • – |
2023-12-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(56,260) |
54,201 |
|
- |
|
| Douglas James Michael |
CHIEF FINANCIAL OFFICER |
• – – |
2023-12-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(31,250) |
20,000 |
|
- |
|
| Maag Peter |
|
– • – |
2023-12-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(62,092) |
58,368 |
|
- |
|
| Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-12-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(308,775) |
87,500 |
|
- |
|
| Heine Lisa Wipperman |
|
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
54,201 |
134,356 |
|
- |
|
| Burke Willaim P |
|
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
54,201 |
134,356 |
|
- |
|
| Buckman Paul |
|
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
54,201 |
106,794 |
|
- |
|
| Erb John L |
|
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
54,201 |
110,461 |
|
- |
|
| Maag Peter |
|
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
54,201 |
120,460 |
|
- |
|
| Douglas James Michael |
CHIEF FINANCIAL OFFICER |
• – – |
2023-03-10 |
4 |
B |
$1.60 |
$50,000 |
D/D |
31,250 |
51,250 |
0.01 |
25% |
|
| Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-03-10 |
4 |
B |
$1.60 |
$50,000 |
D/D |
31,250 |
396,276 |
0.01 |
25% |
|
| Maag Peter |
|
– • – |
2023-03-10 |
4 |
B |
$1.60 |
$50,000 |
D/D |
31,250 |
66,259 |
0.01 |
25% |
|
| Heine Lisa Wipperman |
|
– • – |
2023-03-10 |
4 |
B |
$1.60 |
$50,000 |
D/D |
31,250 |
80,155 |
0.01 |
25% |
|
| Buckman Paul |
|
– • – |
2023-03-10 |
4 |
B |
$1.60 |
$50,000 |
I/I |
31,250 |
52,593 |
0.01 |
25% |
|
62 Records found
|
|
Page 1 of 3 |
|
|
